Análisis de la mortalidad neonatal en el Hospital Universitario La Fe de Valencia. Años 1971-2009 / Analysis of neonatal mortality in the University Hospital La Fe Valencia. Years 1971-2009

Introducción y objetivos: La mortalidad neonatal (MNN) es un indicador de calidad asistencial básico. El objetivo primario de este estudio ha sido el análisis de la evolución la MNN en el Hospital Universitario La Fe de Valencia (HULF), unidad de nivel IIIc, desde su inauguración en 1971 hasta el año 2009. Objetivos secundarios han sido la valoración de la tasa de prematuridad (PR) y bajo peso al nacimiento (BPN). Material y métodos: En este periodo se produjeron 308.989 nacimientos, en los que hubo 2.135 muertes neonatales. Resultados: La MNN muestra un descenso significativo (10,18‰ en 1971 vs 6,24‰ en 2009, p<0,001) Este descenso es aún más significativo para los neonatos con peso al nacimiento entre 500-999 gramos (923,1‰ en 1980 vs 238,1‰ en 2009, p<0,0001) y menor para los prematuros con edad gestacional inferior a 28 semanas (403,8‰ en 1993 vs 287,9‰ en 2009, p<0,01). La tasa de PR paso de 8,7% (1993) al 14% (2009) p<0,001. La tasa de BPN ascendió del 5,3% (1979) al 12.8% (2009), p<0,001. Los varones representan el 58,2% de las muertes neonatales y estas se producen en las primeras 24 h de vida en el 48,2%. La patología respiratoria representa el 36,3% de las muertes neonatales, las malformaciones severas el 31,5%, la patología neurológica el 14,6% y las infecciones el 7,9%. Conclusiones: A pesar del aumento de la PR y BPN se ha conseguido un descenso significativo de la MNN en el HULF(AU)

Background and objectives: Neonatal mortality (NM) is a reliable marker of quality clinical care. The primary objective of this study was to analyse evolution of NM in the Division of Neonatology (level IIIc according to the Spanish Classification) University Hospital La Fe Valencia (HULF) from the beginning of its activity in 1971 until 2009. Secondary objectives were the evaluation of prematurity rate (PR) and low birth weight rate (LBWR). Material and methods: There was a total of 308,989 births, with 2.135 neonatal deaths (ND), during the period studied. Results: NM has shown a significant decrease (10.18% in 1971 vs. 6.24% in 2009; P<0.01). This decrease was even more significant for neonates with birth weight between 500-999g (923.1% in 1980 vs. 238.1% in 2009; P<0.0001) and less for preterm with gestational age less than 28 weeks (403.8% in 1993 vs. 287.9% in 2009; P<0.01). The Prematurity rate increased from 8.7% (1993) to 14% (2009) (P<0.01), and LBWR increased from 5.3% (1979) to 12.8% (2009) (P<0.001). Males represent 58.2% of ND, and these occurred in the first day of life in 48.2% of the cases. Respiratory conditions represent 36.3% of ND, severe congenital malformations 31.5%, neurologic conditions 14.6%, and infections 7.9%. Conclusions: In spite of the increase in LBWR and PR, a significant descent of NM has been achieved in the HULF in the last decades(AU)

[Analysis of neonatal mortality in the University Hospital La Fe Valencia. Years 1971-2009]. / Análisis de la mortalidad neonatal en el Hospital Universitario La Fe de Valencia. Años 1971-2009.

BACKGROUND AND OBJECTIVES: Neonatal mortality (NM) is a reliable marker of quality clinical care. The primary objective of this study was to analyse evolution of NM in the Division of Neonatology (level IIIc according to the Spanish Classification) University Hospital La Fe Valencia (HULF) from the beginning of its activity in 1971 until 2009. Secondary objectives were the evaluation of prematurity rate (PR) and low birth weight rate (LBWR). MATERIAL AND METHODS: There was a total of 308,989 births, with 2.135 neonatal deaths (ND), during the period studied. RESULTS: NM has shown a significant decrease (10.18% in 1971 vs. 6.24% in 2009; P<.01). This decrease was even more significant for neonates with birth weight between 500-999g (923.1% in 1980 vs. 238.1% in 2009; P<.0001) and less for preterm with gestational age less than 28 weeks (403.8% in 1993 vs. 287.9% in 2009; P<.01). The Prematurity rate increased from 8.7% (1993) to 14% (2009) (P<.01), and LBWR increased from 5.3% (1979) to 12.8% (2009) (P<.001). Males represent 58.2% of ND, and these occurred in the first day of life in 48.2% of the cases. Respiratory conditions represent 36.3% of ND, severe congenital malformations 31.5%, neurologic conditions 14.6%, and infections 7.9%. CONCLUSIONS: In spite of the increase in LBWR and PR, a significant descent of NM has been achieved in the HULF in the last decades.

[Respiratory care in neonatal intensive care units. Situation in the year 2005]. / Asistencia respiratoria en las unidades de cuidados intensivos neonatales en España: situación en 2005.

AIM: To learn the characteristic of the neonatal intensive care units (NICUs) that offer neonatal respiratory assistance in Spain. MATERIAL AND METHOD: A structured survey was developed and sent to all Spanish neonatal units to learn about the respiratory care offered in 2005. RESULTS: A total of 96 Units answered the survey, with an estimated representatively of 63%, with a range from 3 to 92%, depending on the geographical area. Level IIIc Units were in the upper range. Answer the survey 26 units type IIb (27%), 16 IIIa (17%), 40 IIIb (42%) and 14 IIIc (14%). The total number of level III NICU beds was 541 (1.2 beds per 1000 livebirths; range, 0.7-1.7). The mean number of beds per NICU was 4.1 in level IIIa Units, 2.8 in those IIIb and 14.6 in type IIIc NICUs. In level III NICUs, the bed per physician ratio was 2.4 and that of beds per registered nurse was 2.8 (2.2 in level IIIc NICUs). There were a total 13,219 admissions, 54% of those needed mechanical ventilation (36% in IIIa and 65% in level IIIc NICUs). Oxygen blenders for resuscitation at birth were available in 42% of level IIIb and IIIc NICUs. NICUs had one neonatal ventilator per bed, and 63% of units had high frequency ventilation available. All units had nasal-CPAP systems, 25% of level IIIa Units, 58% IIIb and 64% of those type IIIc had systems for nasal ventilation. All level IIIc and 93% of level IIIb NICUs were able to provide inhaled nitric oxygen therapy. Four NICUS offered ECMO. CONCLUSIONS: The mean number of NICU beds per 1000 livebirths is within the lower limits of those been recommended, and there were wide variations among different geographical areas. A 54% of those babies admitted to NICUs required mechanical ventilation. The mean number of NICU beds per registered nurse was 2.8. There was an adequate number of neonatal ventilators (one per bed) and 63% were able to provide HFV. All NICUs hand n-CPAP systems.

Asistencia respiratoria en las unidades de cuidados intensivos neonatales en España: situación en 2005 / Respiratory care in neonatal intensive care units. Situation in the year 2005

Objetivo: conocer el tipo de unidades de cuidados intensivos neonatales (UCIN) que proporcionan asistencia respiratoria neonatal en España y sus características. Material y método: encuesta multicéntrica estructurada para conocer la actividad asistencial respiratoria prestada por las UCIN en 2005. Resultados: contestaron 96 unidades neonatales con una representatividad estimada en un 63%, con un intervalo entre el 3 y el 92%, según las áreas geográficas; las unidades IIIc se encuentran en el rango superior. Contestaron la encuesta 26 unidades tipo IIb (27%), 16 IIIa (17%), 40 IIIb (42%) y 14 IIIc (14%). Las camas totales de intensivos de nivel III fue de 541 (1,2 camas cada 1.000 recién nacidos vivos; intervalo, 0,7-1,7). La media de camas por unidad fue de 4,1 para las IIIa, 2,8 para las IIIb y 14,6 para las IIIc. En las unidades de nivel III, la relación camas/médicos fue de 2,4 camas/medico y la de camas/enfermeras 2,8 camas/enfermera (2,2 en nivel IIIc). Hubo un total de 13.219 ingresos, de los que el 54% precisó ventilación (el 36% en las IIIa y el 65% en las IIIc). La posibilidad de reanimación en el paritorio con mezcla de gases (aire y oxígeno) sólo la tiene el 42% de las IIIb y IIIc. La relación respirador/cama fue de 1/1; el 63% puede proporcionar ventilación de alta frecuencia (VAF). Todas disponen de sistemas de presión positiva continua nasal (CPAP-n). Sistemas para aplicar ventilación nasal intermitente están disponibles en el 25% de las IIIa, el 58% de las IIIb y el 64% de las IIIc. Todas las IIIc y el 93% de las IIIb pueden proporcionar oxido nítrico inhalado. Cuatro unidades disponían de ECMO. Conclusiones: la media de camas de UCIN de nivel III cada mil nacidos está en el límite bajo de lo recomendable, con notables diferencias regionales. La necesidad de ventilación mecánica fue del 54%. La relación de camas por enfermera fue de 2,8. Existe una buena dotación de respiradores (1 por cama) con alta disponibilidad de VAF (63%). Todas las unidades disponen de CPAP-n (AU)

Aim: To learn the characteristic of the neonatal intensive care units (NICUs) that offer neonatal respiratory assistance in Spain. Material and method: A structured survey was developed and sent to all Spanish neonatal units to learn about the respiratory care offered in 2005. Results: A total of 96 Units answered the survey, with an estimated representatively of 63%, with a range from 3 to 92%, depending on the geographical area. Level IIIc Units were in the upper range. Answer the survey 26 units type IIb (27%), 16 IIIa (17%), 40 IIIb (42%) and 14 IIIc (14%). The total number of level III NICU beds was 541 (1.2 beds per 1000 livebirths; range, 0.7–1.7). The mean number of beds per NICU was 4.1 in level IIIa Units, 2.8 in those IIIb and 14.6 in type IIIc NICUs. In level III NICUs, the bed per physician ratio was 2.4 and that of beds per registered nurse was 2.8 (2.2 in level IIIc NICUs). There were a total 13,219 admissions, 54% of those needed mechanical ventilation (36% in IIIa and 65% in level IIIc NICUs). Oxygen blenders for resuscitation at birth were available in 42% of level IIIb and IIIc NICUs. NICUs had one neonatal ventilator per bed, and 63% of units had high frequency ventilation available. All units had nasal-CPAP systems, 25% of level IIIa Units, 58% IIIb and 64% of those type IIIc had systems for nasal ventilation. All level IIIc and 93% of level IIIb NICUs were able to provide inhaled nitric oxygen therapy. Four NICUS offered ECMO. Conclusions: The mean number of NICU beds per 1000 livebirths is within the lower limits of those been recommended, and there were wide variations among different geographical areas. A 54% of those babies admitted to NICUs required mechanical ventilation. The mean number of NICU beds per registered nurse was 2.8. There was an adequate number of neonatal ventilators (one per bed) and 63% were able to provide HFV. All NICUs hand n-CPAP systems (AU)

[Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis]. / Ibuprofeno frente a indometacina para el tratamiento de la persistencia del conducto arterioso del prematuro: revisión sistemática y metaanálisis.

INTRODUCTION: Persistent patent ductus arteriosus (PDA) is a common pathology in the preterm whose traditional treatment has been indomethacin. Recently, ibuprofen has shown its effectiveness in closing the PDA with less hemodynamic effects. The objective of this paper is to review the current literature in order to determine if there is any benefit of ibuprofen versus indomethacin in the PDA therapy. MATERIAL AND METHODS: Eleven trials comparing intravenous ibuprofen versus indomethacin in the treatment of PDA confirmed by echocardiography in < 35 weeks preterm or < 1,500 g birth weight were included. A meta-analysis of the trials data was performed. RESULTS: No trial show statistically significant differences in the failure of closing PDA, neither the meta-analysis (RR 0.96 [CI 95 %: 0.74-1.26], with a power of 0.995). No differences were found in the rate of reopening and surgical ligation. Complications were similar, except for a significant lower incidence of oliguria in the ibuprofen group (RR 0.23 [CI 95 %: 0.10-0.51]). There were no differences in the respiratory outcomes (RR of bronchopulmonary dysplasia (BPD) at 28 days 1.32 [CI 95 %: 0.99-1.76]). CONCLUSIONS: In our revision ibuprofen was as effective as indomethacin in closing PDA. No significant differences were found in the incidence of complications except for less renal impairment with ibuprofen. A higher risk of BPD in the ibuprofen group is not confirmed, although more studies are needed.

Ibuprofeno frente a indometacina para el tratamiento de la persistencia del conducto arterioso del prematuro: revisión sistemática y metaanálisis / Ibuprofen versus indomethacin in the preterm persistent patent ductu sarteriosus therapy: review and meta-analysis

Introducción El ductus arterioso persistente (DAP) es una patología frecuente en el recién nacido prematuro cuyo tratamiento tradicional ha sido la indometacina. Recientemente, el ibuprofeno ha mostrado ser eficaz en su cierre con menores efectos hemodinámicos. El objetivo de este trabajo es revisar la literatura disponible para determinar si existe alguna ventaja entre ambos fármacos en el tratamiento del DAP. Material y métodos Se incluyeron 11 ensayos que compararon ibuprofeno con indometacina en el tratamiento del DAP confirmado ecográficamente en prematuros de menos de 35 semanas o de menos de 1.500 g de peso al nacimiento. Se realizó un metaanálisis de los resultados aportados por los distintos estudios. Resultados Ningún estudio encontró diferencias significativas en el fracaso del cierre del DAP entre ambos fármacos, ni el metaanálisis tampoco (riesgo relativo [RR]: 0,96; intervalo de confianza [IC] del 95 %: 0,74 a 1,26], con un poder de 0,995). No hubo diferencias en la frecuencia de reaperturas ni de ligaduras quirúrgicas. Las complicaciones fueron similares, excepto una incidencia significativamente menor de oliguria en los tratados con ibuprofeno (RR: 0,23; IC 95 %: de 0,10 a 0,51). No se encontraron diferencias en la evolución respiratoria (RR de displasia broncopulmonar a los 28 días de 1,32; IC 95 %: de 0,99 a 1,76). Conclusiones En nuestra revisión, el ibuprofeno fue igual de eficaz que la indometacina en el cierre del DAP. No hubo diferencias en la incidencia de complicaciones excepto menores problemas renales con el ibuprofeno. No se confirma un mayor riesgo de displasia broncopulmonar en el grupo de ibuprofeno, aunque se necesitan más estudios al respecto

Introduction Persistent patent ductus arteriosus (PDA) is a common pathology in the preterm whose traditional treatment has been indomethacin. Recently, ibuprofen has shown its effectiveness in closing the PDA with less hemodynamic effects. The objective of this paper is to review the current literature in order to determine if there is any benefit of ibuprofen versus indomethacin in the PDA therapy. Material and methods Eleven trials comparing intravenous ibuprofen versus indomethacin in the treatment of PDA confirmed by echocardiography in < 35 weeks preterm or < 1,500 g birth weight were included. A meta-analysis of the trials data was performed. Results No trial show statistically significant differences in the failure of closing PDA, neither the meta-analysis (RR 0.96 [CI 95 %: 0.74-1.26], with a power of 0.995). No differences were found in the rate of reopening and surgical ligation. Complications were similar, except for a significant lower incidence of oliguria in the ibuprofen group (RR 0.23 [CI 95 %: 0.10-0.51]). There were no differences in the respiratory outcomes (RR of bronchopulmonary dysplasia (BPD) at 28 days 1.32 [CI 95 %: 0.99-1.76]). Conclusions In our revision ibuprofen was as effective as indomethacin in closing PDA. No significant differences were found in the incidence of complications except for less renal impairment with ibuprofen. A higher risk of BPD in the ibuprofen group is not confirmed, although more studies are needed

[Effect of the concomitant administration of indomethacin or ibuprofen on amikacin pharmacokinetics in premature newborns]. / Efecto de la administración concomitante de indometacina o ibuprofeno en la farmacocinética de amikacina en neonatos prematuros.

OBJECTIVE: To evaluate whether the concomitant administration of ibuprofen or indomethacin plus amikacin may alter the latter drug s pharmacokinetic parameters, and hence amikacin plasma levels. METHOD: Retrospective cohort study performed by reviewing the medical records of premature children with persistent ductus arteriosus receiving amikacin and ibuprofen, or amikacin and indomethacin. They were divided up into three groups: group 1: treatment with amikacin went before indomethacin or ibuprofen; group 2: simultaneously treated with amikacin and indomethacin; group 3: simultaneously treated with amikacin and ibuprofen. Pharmacokinetic parameters, distribution volume, and amikacin clearance were measured using the PKS program (a non-linear regression method). Half life was determined from previous parameters. RESULTS: Twenty-eight patients were included. No statistically significant differences were found among pharmacokinetic parameters corresponding to each study group. CONCLUSIONS: Further studies are needed with a greater number of patients and currently recommended doses to assess the influence of indomethacin and ibuprofen in the pharmacokinetics of amikacin in premature children with persistent ductus arteriosus.

Quilotórax neonatal congénito y posquirúrgico: revisión y algoritmo diagnóstico-terapéutico / Congenital and postoperative chylothorax in newborns: review and diagnostic and therapeutic algorithm

El quilotórax se define como la acumulación de linfa en el espacio pleural. Realizamos un estudio retrospectivo durante un periodo de 14 años, en el que encontramos 15 casos de quilotórax neonatal: 6 congénitos y 9 posquirúrgicos. En los casos congénitos hubo dos casos de hydrops y uno se asoció a feblectasia congénita. Los posquirúrgicos fueron 4 tras cirugía cardiovascular y 5 tras cirugía de reparación de hernias diafragmáticas. La evolución fue buena en los 15 pacientes, con resolución del quilotórax. Todos los casos congénitos fueron diagnosticados prenatalmente mediante ecografía fetal, precisando todos reanimación profunda y/o ventifación mecánica tras el nacimiento. El diagnóstico fue confirmado mediante análisis del líquido pleural. El tratamiento inicial fue conservador en todos los casos, con drenaje del líquido pleural y soporte respiratorio, cardiovascular, hemodinámico y nutricional. Este tratamiento fue efectivo en el 80% de los casos, precisando cirugía sólo 3 quilotórax posquirúrgicos. No hemos encontrado diferencias significativas respecto a los volúmenes drenadas, los días de ventilación mecánica, los días de nutrición parenteral total, la duración del quilotórax y el porcentaje de complicaciones entre los casos congénitos y los posquirúrgicos. En el caso de los congénitos, es importante el diagnóstico prenatal para planificar una reanimación neonatal adecuada. Tras la revisión actual, proponemos un algoritmo de manejo de esta compleja patología

Chylothoraxis defined as an effusion of lymphin to the pleural cavity. In a retrospective study covering a 14-year period, we found 15 cases of chylothorax occurring during the neonatal period: 6 congenital and 9 postoperative. Congenital chylothorax was associated with hydrops in two cases and with congenital phlebectasia in one case. Postoperative chylothorax occurred after cardiovascula surgery in tour cases and after surgical repair of diaphragmatic hernia in five. The clinical outcome was good in all the patients. Congenital chylothorax was diagnosed by prenatal ultrasound, and mechanical ventilation was required after birth in every case. The diagnosis was confírmed by the analysis of the pleural fluid. Initial treatment was conservative, with continuous or intermittent drainage of chyle and respiratory, cardiovascular, hemodynamic and nutritional support, which was effective in 80% of the cases. Three patients with postoperative chylothorax required surgery for resolution. We have observed no significant differences between the two groups in terms of volume of Lymph drained, days on mechanical ventilation, days with total parenteral nutrition, duration of chylothorax or complications. Prenatal diagnosis is important for planning neonatal resuscitation. We propase an algorithm for the diagnosis and treatment of this complex entity

Efecto de la administración concomitante de indometacina o ibuprofeno en la farmacocinética de amikacina en neonatos prematuros / No disponible

Objetivo: Evaluar si la administración concomitante de ibuprofenoo indometacina puede alterar los parámetros farmacocinéticosde amikacina y, por lo tanto, los niveles plasmáticos de lamisma.Método: Estudio de cohortes retrospectivo mediante revisiónde historias clínicas correspondientes a niños prematuros con ductusarterioso persistente tratados con amikacina e ibuprofeno, obien amikacina e indometacina. Se ditribuyen en tres grupos: grupo1: el tratamiento con amikacina fue previo a la administraciónde indometacina o ibuprofeno; grupo 2: tratados simultáneamentecon amikacina e indometacina; grupo 3: tratados simultáneamenteamikacina e ibuprofeno. Los parámetros farmacocinéticos,volumen de distribución y aclaramiento de amikacina se determinaronmediante el programa PKS (método de regresión no lineal).La semivida se determinó a partir de los parámetros anteriores.Resultados: Se incluyen 28 pacientes. No se hallan diferenciasestadísticamente significativas entre los parámetros farmacocinéticoscorrespondientes a cada grupo del estudio.Conclusiones: Serían necesarios estudios con mayor númerode pacientes y con las dosis recomendadas actualmente, en losque se evalúe la influencia de indometacina e ibuprofeno en la farmacocinéticade amikacina en niños prematuros con ductus arteriosopersistente

Objective: To evaluate whether the concomitant administrationof ibuprofen or indomethacin plus amikacin may alter the latterdrug's pharmacokinetic parameters, and hence amikacin plasmalevels.Method: Retrospective cohort study performed by reviewingthe medical records of premature children with persistent ductusarteriosus receiving amikacin and ibuprofen, or amikacin andindomethacin. They were divided up into three groups: group 1:treatment with amikacin went before indomethacin or ibuprofen;group 2: simultaneously treated with amikacin and indomethacin;group 3: simultaneously treated with amikacin and ibuprofen.Pharmacokinetic parameters, distribution volume, and amikacinclearance were measured using the PKS program (a non-linearregression method). Half life was determined from previous parameters.Results: Twenty-eight patients were included. No statisticallysignificant differences were found among pharmacokinetic parameterscorresponding to each study group.Conclusions: Further studies are needed with a greater numberof patients and currently recommended doses to assess theinfluence of indomethacin and ibuprofen in the pharmacokineticsof amikacin in premature children with persistent ductus arteriosus

¿Se debe formar el residente de Pediatría en Atención Primaria? ¿Por qué? Encuesta a pediatras y residentes de Valencia / No disponible

Introducción y objetivos: considerando que el residente de Pediatría no se forma en puericulturani en prevención y promoción de salud del niño sano en centros de Atención PediátricaPrimaria, ni para el tratamiento del niño que no precisa atención hospitalaria, se intentasaber si el residente debe formarse en Atención Primaria.Material y métodos: para ello se distribuyó una encuesta anónima dirigida a todos lospediatras que prestan la Atención Primaria en la ciudad de Valencia, a todos los pediatras delHospital La Fe y a todos los residentes de Pediatría de dicho hospital. Se preguntó: ¿Creesque el residente de Pediatría debe rotar –también– por un centro de Atención Primaria acreditadopara completar su formación? Y ¿por qué?Resultados: se obtuvo un porcentaje de respuesta del 44,7%. El 86% respondió sí, el13% no y el 1% en blanco. Dijeron sí el 90% de los pediatras (95% de Primaria y 83% dehospital) y el 50% de los residentes. Los encuestados respondieron a la segunda parte de lapregunta y aportaron su opinión respecto a los motivos a favor de la rotación en AtenciónPediátrica Primaria; el 29% aportó ideas respecto al programa de formación del residente. El13% que opinó que no debe rotar justificó su opinión y aportó ideas para la formación delresidente. Conclusiones: el 86% de encuestados opina que el residente de Pediatría debe rotar porAtención Primaria para completar su formación y el 17% reclama alargar a más de cuatro añosla especialidad de Pediatría

Introduction and objectives: considering that the resident physician in the specialty ofpaediatrics in Valencia never trains in Paediatric Primary Care centres and that he does notreceive any preparation in child care nor in aspects as preventive care and promotion of goodhabits in healthy children or the treatment of ill children who do not need hospitalization,our intention is to find out if residents should be trained in Paediatric Primary Care, accordingto the opinion of paediatricians and residents in paediatrics.Material and methods: for this reason, an anonymous survey was carried out directed toall paediatricians in Primary Care in the city of Valencia and to all paediatricians and residentsin paediatrics who practise hospital care in the Hospital La Fe. The questions were: Doyou think that a paediatric resident should train –additionally– in an accredited primary healthcare center in order to complete his training? Why?Results: a percentage of 44.7% answered. Eighty-six per cent answered yes, 13% no and1% blank. Affirmative responses were from 90% of the paediatricians (95% primary carepaediatricians and 85% hospital care paediatricians) and 50% of the residents. Those surveyedresponded to the second part of the question giving their opinion on the motives in favourof Paediatric Primary Care training. 29% offered ideas for the resident training program,the 13% against Paediatric Primary Care training, that justified with their opinions.Conclusions: 86% say the resident should be trained in Paediatric Primary Care and17% demand more than four years’ training in Paediatrics

[Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants]. / Ibuprofeno frente a indometacina en el tratamiento del conducto arterioso persistente del prematuro.

INTRODUCTION: Persistent patent ductus arteriosus (PDA) is a common entity in preterm infants. The most commonly used pharmacological treatment to close the ductus is indomethacin but it can affect cerebral, renal and mesenteric blood flow. Ibuprofen has recently been shown to be effective in closing PDA with fewer hemodynamic effects. In this study we compared the safety and efficacy of ibuprofen and indomethacin in the treatment of PDA in preterm infants. MATERIAL AND METHODS: A randomized trial was performed. Premature infants with symptomatic PDA confirmed by echocardiography in the first week of life and who required respiratory support were included. The patients were randomly assigned to receive either intravenous indomethacin or ibuprofen. The rate of ductal closure, need for additional treatment, complications, and clinical course were evaluated. RESULTS: Twenty-four patients were treated with indomethacin and 23 with ibuprofen. The clinical characteristics before treatment were similar in both groups. Both treatments were effective in closing PDA (87.5% in the indomethacin group and 82.6% in the ibuprofen group). The two cohorts did not differ in the rate of reopening, need for a second pharmacologic treatment, or surgical ductal ligation. No patient in the ibuprofen group developed gastrointestinal adverse effects, but two infants in the indomethacin group had isolated bowel perforation and one had necrotizing enterocolitis. Transient renal dysfunction developed in seven patients (29%) in the indomethacin group versus two (9%) in the ibuprofen group. Transient renal insufficiency was found in one patient in the indomethacin group and in none in the ibuprofen group. The rate of other complications was similar in both groups. CONCLUSIONS: In our trial ibuprofen was as effective as indomethacin in closing PDA. No significant differences were found in the incidence of complications but fewer renal complications and no gastrointestinal complications were found in the ibuprofen group.

Ibuprofeno frente a indometacina en el tratamiento del conducto arterioso persistente del premature / Ibuprofen versus indomethacin in the treatment of patient ductus arteriosus in preterm infants

Introducción. El conducto (ductus) arterioso persistente (DAP) es una enfermedad frecuente en el prematuro. La indometacina es el tratamiento más utilizado en su cierre, pero puede alterar el flujo cerebral, renal y mesentérico. Recientemente el ibuprofeno ha mostrado ser eficaz en el cierre del DAP con menores efectos hemodinámicos. Este estudio se realizó para comparar la eficacia y seguridad del ibuprofeno frente a la indometacina en el cierre del DAP en el prematuro. Material y métodos. Estudio aleatorizado que incluyó prematuros con DAP sintomáticos, diagnosticados mediante ecografía en la primera semana de vida, que precisaron soporte ventilatorio. Los pacientes fueron asignados aleatoriamente a indometacina o ibuprofeno por vía intravenosa. Se evaluó la tasa de cierre ductal, la necesidad de tratamiento adicional, las complicaciones y la evolución clínica. Resultados. Se trataron 24 pacientes con indometacina y 23 con ibuprofeno. Sus características clínicas previas al diagnóstico fueron similares. Ambos tratamientos se mostraron eficaces en el cierre, 87,5 % para la indometacina y 82,6 % para el ibuprofeno. Las dos cohortes no se diferenciaron en la frecuencia de reaperturas, necesidad de dos tandas de fármaco, ni proporción de ligaduras quirúrgicas. Ningún paciente tratado con ibuprofeno presentó enfermedad abdominal que sí apareció en el grupo de indometacina (dos perforaciones intestinales y una enterocolitis necrosante). Siete pacientes (29 %) del grupo de indometacina desarrollaron disfunción renal transitoria frente a 2 casos (9 %) en el de ibuprofeno. En el grupo de indometacina un paciente experimentó insuficiencia renal transitoria y ninguno en el de ibuprofeno. El resto de complicaciones fue similar en ambos grupos. Conclusiones. En nuestra serie el ibuprofeno se mostró igual de eficaz que la indometacina en el cierre del DAP. No hubo diferencias significativas en la incidencia de complicaciones entre ambos grupos, aunque los tratados con ibuprofeno tuvieron menos complicaciones renales y ninguna intestinal

Introduction. Persistent patent ductus arteriosus (PDA) is a common entity in preterm infants. The most commonly used pharmacological treatment to close the ductus is indomethacin but it can affect cerebral, renal and mesenteric blood flow. Ibuprofen has recently been shown to be effective in closing PDA with fewer hemodynamic effects. In this study we compared the safety and efficacy of ibuprofen and indomethacin in the treatment of PDA in preterm infants. Material and methods. A randomized trial was performed. Premature infants with symptomatic PDA confirmed by echocardiography in the first week of life and who required respiratory support were included. The patients were randomly assigned to receive either intravenous indomethacin or ibuprofen. The rate of ductal closure, need for additional treatment, complications, and clinical course were evaluated. Results. Twenty-four patients were treated with indomethacin and 23 with ibuprofen. The clinical characteristics before treatment were similar in both groups. Both treatments were effective in closing PDA (87.5 % in the indomethacin group and 82.6 % in the ibuprofen group). The two cohorts did not differ in the rate of reopening, need for a second pharmacologic treatment, or surgical ductal ligation. No patient in the ibuprofen group developed gastrointestinal adverse effects, but two infants in the indomethacin group had isolated bowel perforation and one had necrotizing enterocolitis. Transient renal dysfunction developed in seven patients (29 %) in the indomethacin group versus two (9 %) in the ibuprofen group. Transient renal insufficiency was found in one patient in the indomethacin group and in none in the ibuprofen group. The rate of other complications was similar in both groups. Conclusions. In our trial ibuprofen was as effective as indomethacin in closing PDA. No significant differences were found in the incidence of complications but fewer renal complications and no gastrointestinal complications were found in the ibuprofen group

[Nasal continuous positive airway pressure in preterm infants: comparison of two low-resistance models]. / Presión positiva continua en la vía aérea por vía nasal en el recién nacido prematuro: estudio comparativo de dos modelos de baja resistencia.

OBJECTIVE: To compare the safety and efficacy of two low expiratory resistance models of nasal continuous positive airway pressure (n-CPAP) in preterm infants. MATERIAL AND METHODS: A 1-year prospective trial was performed in the Neonatal Intensive Care Unit of La Fe Hospital to compare the Infant Flow (IF) and Medijet (MJ) devices. All preterm infants requiring n-CPAP for respiratory distress at birth (group I), infants weighting less than 1500 g requiring postextubation (group II) and those with apnea-bradycardia syndrome (ABS) (group III) were included. The patients were randomly assigned to IF or MJ. RESULTS: A total of 125 patients received 226 treatments (IF: n 5 126: MJ: n 5 110). The mean gestational age was 29.4 weeks and the mean birth weight was 1340 g.Efficacy. In group I (n 5 73) no difference were found between systems and 6 hours' after initiation of n-CPAP decreases in FiO2, CO2 and respiratory effort were similar. The need for intubation was also similar (IF: 34.6 %; MJ: 24.1 %). In group II (n 5 73) the need for reintubation at 48 hours was similar with both treatments (IF:19 %; MJ: 8 %). In group III (n 5 80) resolution of ABS was similar after 24 hours of n-CPAP (IF: 46 %; MJ: 58 %). The need for intubation was also similar (IF: 26 %; MJ: 10 %).Complications. Air leaks occurred in six preterm infants (IF: 4; MJ: 2). Severe abdominal distension occurred in 5 % with both systems. Five infants had significant nasal lesions (IF: 1; MJ: 4). CONCLUSIONS: The efficacy and safety of both systems was similar in the variables studied and no significant differences were found.

Presión positiva continua en la vía aérea por vía nasal en el recién nacido prematuro: estudio comparativo de dos modelos de baja resistencia / Nasal continuous positive airway pressure in preterm infants: comparison of two low-resistance models

Objetivo: Comparar la eficacia y seguridad de dos modelos diferentes de presión positiva continua en la vía aérea por vía nasal (CPAP-n) de baja resistencia, en recién nacidos pretérminos. Material y métodos: Estudio prospectivo realizado en cuidados intensivos neonatales del Hospital La Fe durante un año, comparando los sistemas Infant Flow (IF) y Medijet (MJ). Se incluyeron todos los pretérminos que precisaron CPAP-n por distrés respiratorio al ingreso (grupo I), postextubación en menores de 1.500 g al nacimiento (grupo II) y síndrome apneico-bradicárdico (grupo III); asignación aleatoria a uno u otro sistema. Resultados: Estudiamos 125 pacientes, que recibieron 226 tratamientos; 126 con IF y 110 con MJ. Media edad gestacional, 29,4 semanas, y peso al nacimiento, 1.340 g. Eficacia. Grupo I (n 73): no hubo diferencias entre los 2 modelos consiguiéndose a las 6 h del inicio de CPAP-n descensos de la fracción inspiratoria de oxígeno (FiO2), presión parcial de dióxido de carbono (pCO2) y esfuerzo respiratorio; necesidad similar de intubación y ventilación (34,6 por ciento IF y 24,1 por ciento MJ). Grupo II (n 73): porcentaje de reintubación semejante a 48 h (19 por ciento IF y 8 por ciento MJ). Grupo III (n 80): tras 24 h de CPAP-n desaparecieron las apneas en proporción similar (46 por ciento IF y 58 por ciento MJ); precisaron intubación y ventilación 24 por ciento del IF y 10 por ciento del MJ. Complicaciones. Escapes aéreos: 6 pacientes (4 IF y 2 MJ). Distensión abdominal grave: similar con ambos sistemas (5 por ciento). Lesión nasal significativa: 5 pacientes (1 IF y 4 MJ).Conclusiones Los dos sistemas de CPAP-n han sido efectivos y seguros en los supuestos estudiados, sin diferencias significativas en los resultados (AU)

[The Europe against immature lung (EURAIL) project. Strategies for the prevention and treatment of lung immaturity in neonates]. / Proyecto EURAIL. Estrategias de prevención y tratamiento contra la inmadurez pulmonar en España.

OBJECTIVE: To determine clinical practice variability in the prevention and postnatal treatment of lung immaturity in Spain. PATIENTS AND METHODS: Cross-sectional study within a larger study in 13 European countries. Data were obtained from the medical records of all very low birth weight (VLBW) infants born in participating centers, without other instrumentation. RESULTS: A questionnaire was sent to 213 centers. Seventy-two (34 %) responded, with 162,157 births (40 % of total births in 1999). Eight percent of infants were of low birth weight, 1.2 % (2,015) of very low birth weight and 0.45 % were of extremely low birth weight. A total of 52.2 % of VLBW infants received at least one dose of prenatal steroids, 28.8 % received a full course and 9.3 % received more than one cycle. All centres used surfactant and 76.8 % had a written protocol. Forty-one percent of VLBW infants were intubated, 47.6 % required mechanical ventilation for more than 6 hours, and 5 % underwent continuous positive airway pressure. A total of 80.4 % used postnatal steroids, half of them for chronic lung disease prevention, and 83.4 % used steroids to treat this disease. Steroids were most frequently indicated at 7-14 days of life for 3-9 days. The most important causes of neonatal morbidity were chronic lung disease in 14 %, ductus arteriosus in 16.7 %, intraventricular hemorrhage in 8.5 %, and necrotizing enterocolitis in 7.3 %. CONCLUSIONS: Prenatal exposure to steroids was low. Repeat cycles and postnatal steroid use to prevent chronic lung disease was high. Recent scientific evidence on the use of pre- and postnatal steroids should be more widely disseminated.

Proyecto EURAIL. Estrategias de prevención y tratamiento contra la inmadurez pulmonar en España / The Europe against immature lung (EURAIL) project. Strategies for the prevention and treatment of lung immaturity in neonates

Objetivo: Conocer la variabilidad de la práctica clínica habitual en la prevención y el tratamiento de la inmadurez pulmonar. Pacientes y métodos Estudio transversal dentro de un estudio en 13 países europeos. De todos los neonatos de muy bajo peso nacidos en los centros colaboradores se recogieron datos de las historias clínicas sin ningún tipo de instrumentación adicional. Resultados La encuesta fue remitida a 213 centros, de los cuales contestaron 72 (34 per cent), con un total de 162.157 nacimientos (40 per cent del total en 1999). El 8 per cent de los recién nacidos eran de bajo peso, el 1,2 per cent de muy bajo peso (2.015) y el 0,45 per cent de extremado bajo peso. El 52,5 per cent de los de muy bajo peso recibieron al menos una dosis de corticoides prenatales, el 28,8 per cent, un ciclo completo, y el 9,3 per cent, más de un ciclo. Todos los centros utilizan algún preparado surfactante, y cuentan con un protocolo escrito el 76,8 per cent. El 41 per cent de los recién nacidos de muy bajo peso fueron intubados al nacer, el 47,6 per cent precisaron ventilación mecánica durante más de 6 h y el 5 per cent presión positiva continua. El 80,4 per cent de centros usaban corticoides posnatales, la mitad para la prevención de enfermedad pulmonar crónica (EPC) y el 83,4 per cent como de terapéutica. La pauta más habitual era indicarlos a los 7-14 días de vida, durante 3-9 días. Entre la morbilidad neonatal destaca la EPC (14 per cent), conducto arterioso sintomático (16,7 per cent), hemorragia intraventricular (8,5 per cent) y enterocolitis necrosante (7,3 per cent). Conclusiones: La tasa de exposición a corticoides prenatales fue baja y la práctica de repetir los ciclos y el empleo de corticoides posnatales para prevenir la EPC elevadas. Sigue siendo preciso difundir la reciente evidencia científica sobre el uso de corticoides prenatales y posnatales (AU)

[Prophylaxis and treatment of respiratory distress syndrome with different surfactants]. / Profilaxis y tratamiento del síndrome de distrés respiratorio con diferentes surfactantes.

BACKGROUND: Etiological treatment of respiratory distress syndrome due to lung immaturity with exogenous surfactant is of proven efficacy. However, it is not clear whether all the exogenous surfactants available, both natural and synthetic, are of equal efficacy. OBJECTIVE: To evaluate whether there is any evidence to support the efficacy of one exogenous surfactant over that of the others in the prophylaxis and treatment of respiratory distress syndrome. METHODS: To identify all the comparative studies of tensoactive compounds, an intensive bibliographic search was performed in several databases. RESULTS: Data was found to corroborate that natural surfactants improve oxygenation more rapidly than synthetic surfactants. Natural surfactants also have lower complication and mortality rates. Of the two natural surfactants available in Spain, the porcine-derived surfactant (poractant-alfa) seems to present some advantages over the bovine-derived surfactant (beractant), such as faster action, expressed as a more favourable PaO2/PAO2 ratio during the first 24 hours of treatment. There is also a trend indicating that newborns treated with porcine surfactant have a lower overall mortality rate (3 %) compared with those treated with bovine surfactant (12.5 %). CONCLUSION: No scientific evidence supports the current use of commercialised synthetic surfactants. The porcine-derived surfactant can be considered as the preparation of choice, although additional studies confirming this finding would be useful.

Profilaxis y tratamiento del síndrome de distrés respiratorio con diferentes surfactantes / Prophylaxis and treatment of respiratory distress syndrome with different surfactants

Antecedentes: El tratamiento etiológico del síndrome de distrés respiratorio (SDR) por inmadurez pulmonar con surfactante exógeno es una estrategia de demostrada eficacia. Sin embargo, la eficacia relativa de los diversos preparados tensiactivos, de origen natural o sintético, puede no ser similar. Objetivo: Evaluar si existe evidencia de que algún preparado o preparados tensiactivos puede considerarse más eficaz en el tratamiento y profilaxis del SDR. Métodos: Se realizó una búsqueda bibliográfica pormenorizada en las diversas bases de datos existentes, para identificar todos los estudios comparativos entre los diversos preparados tensiactivos. Resultados: Existen datos que corroboran que los surfactantes de origen natural producen una más rápida mejoría de la oxigenación, en comparación a los de origen sintético. También se ha observado una menor tasa de complicaciones y de mortalidad con el empleo de surfactantes naturales. De los dos surfactantes naturales comercializados en España, el de origen porcino (poractant alfa) parece presentar ventajas sobre el de origen bovino (beractant), como es una mayor rapidez de actuación, expresada en una relación PaO2/PAO2 más favorable, en las primeras 24 h de tratamiento. Existe también una tendencia a que los enfermos tratados con surfactante porcino tengan una menor tasa de mortalidad global (3%) frente a los tratados con surfactante bovino (12,5%).Conclusión: No existe razón científica alguna que apoye el uso de los surfactantes sintéticos comercializados en la actualidad. El surfactante natural de origen porcino podría considerarse de primera elección, si bien sería conveniente disponer de estudios adicionales que confirmaran este hecho (AU)

Adenomatosis quística pulmonar: nuestra experiencia en los últimos diez años / Congenital cystic adenomatoid malformation of the lung: our experience over the past ten years

La adenomatosis quística pulmonar es una causa inusual de distrés respiratorio neonatal; sin embargo, es la masa torácica de diagnóstico prenatal más frecuente. Describimos diez casos de adenomatosis quística pulmonar diagnosticados durante la primera infancia. Su clínica, radiología y hallazgos patológicos son analizados y comparados con los datos de la literatura (AU)